米特拉米及其类型:分子特征和抗瘤作用
1Instituto de Diagnóstico Ambiental y Estudios del Agua, CSIC, E-08034 Barcelona, Spain.
Pharmacology & therapeutics
|June 5, 2024
概括
甲基甲基甲基相似物 (mithralogs) 通过抑制Sp1和EWS-FLI1转录因子,显示出作为癌症治疗的前景. 这些改性化合物具有较低的毒性和改善了对各种瘤的活性,包括尤文肉瘤.
科学领域:
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 米特拉米A (MTA) 是一种抗瘤抗生素,向富含G/C的DNA和Sp1转录因子.
- 由于毒性,MTA的临床使用已停止,但其潜力正在重新评估.
- 在发育中的瘤中,Sp1转录因子通常被上调.
研究的目的:
- 探索修改后的密拉米辛类似物 (mitralogs) 具有降低毒性和增强药理活性的潜力.
- 为了研究mithralogs在低调基因表达在各种癌症类型的有效性.
- 评估MTA和mithralogs对尤文肉瘤的有效性.
主要方法:
- 修改MTA生物合成途径以创建新的mithralogs.
- 在人类卵巢和前列腺瘤中评估mithralog基因表达调节.
- 通过准EWS-FLI1转录来评估MTA和密特拉洛格在治疗尤宁肉瘤中的疗效.
主要成果:
- 与MTA相比,Mithralogs表现出降低的毒性和改善的药理活性.
- 几种mithralogs有效地降低了人类卵巢和前列腺瘤的基因表达.
- MTA和特定的mithralogs,如EC-8042和EC-8105,在治疗尤文肉瘤方面表现出有效性.
结论:
- 米特拉龙是癌症治疗的一类有前途的化合物.
- 使用密斯拉洛格针对Sp1和EWS-FLI1转录因子提供了一个可行的治疗策略.
- 进一步开发密特洛格可以克服传统MTA治疗的局限性.
相关概念视频
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


